Ariana Boswell

Ariana Boswell received her bachelor's degree in biochemistry from Vassar College and is currently pursuing her Master of Public Health in epidemiology at Columbia University Mailman School of Public Health. She has previously conducted research on rare and chronic diseases at Vassar College and Yale School of Medicine and hopes to remain involved in rare disease research and communications in the future. Ariana joined Rare Disease Advisor in 2024.

All articles by Ariana Boswell

Understanding maintenance therapy in advanced breast cancer

Maintenance therapy can significantly improve overall and progression-free survival in patients with advanced breast cancer.
Fertility preservation options before breast cancer treatment

A breast cancer diagnosis doesn’t mean you can’t have children of your own. There are various options available to help preserve fertility.
First patient dosed in clinical trial for HER2-positive breast cancer

Innovent Biologics has dosed the first patient in their Phase 3 HeriCare-Breast01 trial of IBI354 in HER2-positive breast cancer.
Treatment sequencing in breast cancer: why order matters

The order in which breast cancer treatments are administered can make a major difference in treatment efficacy, quality of life and survival.
FDA approves imlunestrant for advanced and metastatic breast cancer

Imlunestrant has received FDA approval for adults with ER-positive, HER2-negative breast cancer who have mutations in the ESR1 gene.
FDA gives therapy for advanced breast cancer expedited review

Relay Therapeutics has received Breakthrough Therapy designation for zovegalisib and fulvestrant in PIK3CA mutant HR+/HER2- breast cancer.
Clinical trial for triple-negative breast cancer vaccine beginning soon

Immunomic Therapeutics may now begin their clinical trial of ITI-5000, an RNA vaccine, in patients with triple-negative breast cancer.
When and how to pursue a second opinion for breast cancer treatment

Getting a second opinion can help provide you with more information to help you feel more comfortable with your breast cancer care plan.
Clinical trial for potential metastatic breast cancer treatment to begin soon

Atossa Therapeutics received FDA permission to begin their dose-escalating study of (Z)-endoxifen in patients with metastatic breast cancer.
Navigating early menopause due to breast cancer treatment

A potential side effect of breast cancer treatment is early-induced menopause, which can either be permanent or temporary.